Defibrotide (DF), a polydeoxyribonucleotide with antithrombotic properties, has recently proven effective in patients with severe hepatic veno-occlusive disease (VOD), a life-threatening complication of high-dose chemo/radiotherapy regimens for stem cell transplantation. To understand the mechanism of its beneficial effect, we studied the impact of DF on the expression of tissue factor (TF) and fibrinolytic proteins (PAI-1 and t-PA) on endothelial cells. The in vitro response to DF of two types of human endothelial cells (ECs) of different origins, that is from macrovascular (HUVEC) and microvascular (HMEC-1 cell line) beds, was evaluated in the presence or absence of a proinflammatory stimulus (ie bacterial endotoxin, LPS). The results show that DF was able to significantly reduce the LPSinduced TF expression by HMEC-1, and less prominently by HUVEC. In addition, DF importantly influenced the fibrinolytic properties of both HMEC-1 and HUVEC. Specifically, it dosedependently counteracted the LPS-induced increase in PAI-1 levels and decrease in t-PA activity expression. It also significantly incremented t-PA antigen in resting EC. Decreasing the procoagulant activity and increasing the fibrinolytic potential of EC favors an anticoagulant phenotype of the endothelium, which may protect from fibrin deposition and vascular occlusion.
Introduction
Defibrotide (DF) belongs to a class of pharmacological agents derived from nucleic acids. 1 Various in vivo studies have shown that DF possesses antithrombotic properties, without significant systemic anticoagulant effects. [2] [3] [4] This has raised much interest for the use of DF in clinical conditions at high hemorrhagic risk, including severe hepatic veno-occlusive disease (VOD), one of the most dreadful complications of high-dose cyto-reductive therapy for bone marrow or peripheral stem cell transplantations. 5 VOD develops in 10-60% of patients undergoing allogeneic transplantation, but has also been described in autologous and syngeneic transplants. 6 Established severe VOD is associated with a mortality rate of about 100% at day +100 after stem cell transplantation. 6 Treatment of this complication with DF has resulted in a response rate of 35-43%. [7] [8] [9] VOD is characterized by endothelial cell (EC) injury, inflammation and fibrosis leading to occlusion of small hepatic venules. The endothelial damage, caused by chemo-and radiotherapy regimens, represents the initial event, which leads to platelet and coagulative material (fibrinogen and Factor VIII) deposition in the subendothelium of the hepatic sinusoids and venules. 6 Commonly, in malignant disease, the vascular endothelium is exposed to the insults of the different antitumor treatments (ie, chemo-, radio-and hormone therapies) and to inflammatory molecules released by tumor cells and leukocytes. 10 As well documented these insults may exert a thrombogenic role. [11] [12] [13] Therefore, it is of great interest to identify drugs that may protect the vascular wall and reduce the prothrombotic/proinflammatory response of the perturbed endothelium in this condition. 14, 15 In this context, it is important to consider that ECs from different sites can react differently and the microcirculation of peripheral organs may play a crucial role in the pathogenesis of microangiopathies and tissue damage associated with malignancy and stem cell transplantation. 6, 16, 17 DF therapy is effective in resolving VOD, a condition characterized by elevated endothelial toxicity. 6 There are few and incomplete studies on the effects of DF on the hemostatic properties of EC derived from large vessels, 18, 19 and no information at all on DF effect on EC derived from the microvasculature.
We have, here, investigated on the impact of DF on EC features involved in the onset of thrombotic phenomena, such as the expression of procoagulant (tissue factor, TF) and fibrinolytic properties (tissue-plasminogen activator, t-PA, and its inhibitor, PAI-1). The study has been conducted on two different in vitro models of human EC, derived from macro-and microvessels, respectively, in response to bacterial endotoxin as a proinflammatory stimulus.
Materials and methods

Cell cultures
For all assays, two types of endothelial cells were used.
Immortalized human microvascular endothelial cell line-1 (HMEC-1): 20 The HMEC-1 cell line was kindly supplied by Dr FJ Candal (CDC, Centers for Disease Control and Prevention, Atlanta, GA, USA). Presently, this is the best-characterized microvascular EC line. 21 HMEC-1 were grown in RPMI 1640 medium supplemented with 10% fetal calf serum (FCS) (Gibco, Gaithersburg, MD, USA), 100 mg/ml streptomycin, 100 U/ml penicillin, 5 mg/ml amphotericin B (Bristol-Myers Squibb), 2 mmol/l L-glutamine (Gibco), 10 ng/ml epidermal growth factor (ICN, Costa Mesa, CA, USA) and 1 mg/ml hydrocortisone (ICN). HMEC-1 were serially passed in T25 flasks (Falcon, Becton Dickinson, Mountain View, CA, USA) and, at passages 8th to 16th, seeded in 24-well cell culture plates for the experiments.
Human endothelial cells from macrovasculature (HUVEC): HUVEC were freshly isolated from human umbilical cord veins, according to the method described, 22 and grown in T25 flasks in RPMI 1640 medium supplemented with 20% FCS, 100 mg/ml streptomycin, 100 U/ml penicillin, 5 mg/ml amphotericin B and 2 mmol/l L-glutamine. For the experiments, confluent primary cultures were harvested using 0.25% trypsin and 0.02% EDTA (Sigma, St Louis, MO, USA) solution, seeded on the bottom of 24-well cell culture clusters coated with 0.5% gelatin (Sigma) and grown to the confluence.
ECs were grown in a 5% CO 2 /95% air atmosphere and in humidified incubators. At the end of each experiment, ECs were counted by microscopy and trypan blue exclusion test was used to determine cell viability. More than 95% of cells were viable in all experiments. In parallel, the evaluation of apoptosis by Annexin V-propidium iodide staining and flow cytometry analysis showed that apoptosis did not occur upon the various treatments in our experimental conditions. The cell culture medium was checked for endotoxin contamination with limulus amebocyte lysate assay (Chromogenix AB, Molndal, Sweden), and endotoxin concentration was found less than 5 pg/ml at working concentrations of the reagents.
EC procoagulant property (TF)
To evaluate the effect of DF on TF expression, confluent EC monolayers were incubated for 4 h with DF at doses of 12.5, 50, 200 and 800 mg/ml (a kind gift of Gentium SpA, Villa Guardia, Como, Italy) or saline (control cells) in the presence of 10 mg/ml bacterial endotoxin (LPS, Sigma). DF doses were selected on the basis of the concentrations utilized in vivo for therapy. 6, 7 After incubation with DF, EC monolayers were washed three times with phosphate-buffered saline (PBS) pH 7.4, and different EC samples were prepared for the different assays.
TF procoagulant activity (TF-PCA) assay: TF-PCA was evaluated in EC lysates (0.5 Â 10 6 cells/ml PBS), obtained after three cycles of freezing/thawing, by the one-stage recalcification assay of normal human plasma, as described.
14 TF-PCA was identified and characterized as TF by the clotting assay of factor VII-, VIII-or X-deficient human plasmas (FVII-D, FVIII-D, FX-D, DADE Behring, Milan, Italy). In some experiments, TF activity was further characterized by incubating (15 min at 371C) EC samples with a purified polyclonal rabbit IgG antibody (1 mg/ml f.c.) directed against human TF (#4502, American Diagnostica Inc., Greenwich, CT, USA) before the clotting assay. A normal nonimmune rabbit IgG was the control in this assay. TF-PCA was referred to a calibration curve constructed with different dilutions (from 10 À1 to 10
À6
) of a standard rabbit brain thromboplastin (RBT; Sigma). Results are expressed as standard thromboplastin arbitrary units, 1 unit ¼ the activity of 1 mEquiv/ ml of RBT in the coagulation assay.
TF antigen assay:
The levels of TF antigen were measured in EC extracts (0.5 Â 10 6 cells/ml of 50 mmol/l Tris buffer, 100 mmol/l NaCl and 1% triton X-100; pH 7.5) by a commercial ELISA (Imubind Tissue Factor ELISA Kit; American Diagnostica) according to the manufacturer's instructions. 14 Results are expressed as pg/10 5 cells.
EC fibrinolytic parameters
To study the impact of DF on EC fibrinolytic properties, ECs were incubated with DF (12.5-800 mg/ml) or the vehicle (control cells) for up to 72 h. After incubation, conditioned media (CM) were collected at 24-h intervals, 0.22 mm-filtered to eliminate cell debris and stored at À801C. Then the levels of PAI-1 and t-PA antigens and t-PA activity in EC-CM were measured. In subsequent experiments, a 24-h incubation time was selected for HMEC-1 and a 48-h incubation for HUVEC, because these corresponded to the minimum time intervals required to obtain measurable concentrations of fibrinolytic proteins in the two different EC systems. To study the interference of DF with the antifibrinolytic action of LPS, ECs were incubated with 10 mg/ml LPS7DF (12.5-800 mg/ml). t-PA and PAI-1 antigens were measured in CM by ELISA, using commercially available kits (Asserachrom t-PA and PAI-1, respectively, Roche Diagnostics, Monza, Italy) according to the manufacturer's instructions. Results for both the antigens are expressed as ng/10 5 cells. t-PA activity was measured in CM by a commercial chromogenic assay (Coaset t-PA, Instrumentation Laboratory, Monza, Italy). To improve the specificity of the assay, t-PA activity was measured in CM samples before and after the addition of a greater than 98% inhibitory concentration of a goat anti-human-t-PA IgG (20 mg/ml, American Diagnostica Inc.). 23 Results are expressed as IU/10 5 cells.
Statistical analysis
The results are reported as mean 7s.d. from three independent experiments performed in duplicate. Student's paired t-test was used for the determination of significance levels between treatments. Differences were considered statistically significant when Po0.05. 
Results
Effects of DF treatment on EC TF expression
Effects of DF on the fibrinolytic properties of ECs
The study of the effect of DF on EC fibrinolytic proteins was conducted in two different experimental conditions, that is, LPSstimulated and resting EC.
Effects of DF on the fibrinolytic properties of LPSstimulated EC: Incubation of HMEC-1 with 10 mg/ml LPS induced a significant increase in PAI-1 antigen release in the CM (control vs LPS: 5587159 vs 7517154 ng/10 5 cells). The addition of DF dose-dependently counteracted the LPS-induced Figure 1 Effect of defibrotide on TF PCA and antigen expression by HMEC-1 (a and b panels) and HUVEC (c and d panels) stimulated with LPS. ECs were incubated for 4 h with LPS in the presence or absence of increasing concentrations of DF and then tested for TF-PCA and TF antigen. DF significantly counteracted the LPS-induced TF expression by HMEC-1. *Po0.05 of (LPS+DF)-treated cells vs LPS alone. Figure 2 shows the results at 24-h incubation with increasing concentrations of DF in the presence of LPS. Specifically, PAI-1 levels ( Figure 2a . Figure 3a -c shows the results at 48-h incubation with LPS in the presence or absence of increasing concentrations of DF. As observed for HMEC-1, the induction of PAI-1 by LPS in HUVEC was dose-dependently prevented by the concomitant treatment with DF (Figure 3a) . In addition, DF enhanced the LPS-induced increase of t-PA antigen expression (Figure 3b ) and significantly prevented the LPSinduced reduction of t-PA activity (Figure 3c ).
Defibrotide and endothelium
Effects of DF on the fibrinolytic properties of unstimulated EC: HMEC-1 and HUVEC were incubated with increasing concentrations of DF for up to 72 h in the absence of any stimulus. The levels of PAI-1 and t-PA antigens and t-PA activity were measured in EC CM collected at every 24 h of incubation. Figure 4 shows the results obtained after incubating HMEC-1 with 200 mg/ml DF for 24 h and HUVEC for 48 h. Different Figure 3 Effect of defibrotide on fibrinolytic proteins by HUVEC stimulated with LPS. HUVEC were incubated with LPS in the presence or absence of DF. After 48 h incubation, CM were collected and tested for PAI-1 and t-PA antigens and for t-PA activity. Also in these EC, DF significantly counteracted the antifibrinolytic action of LPS.
y Po0.05 of LPS-treated cells vs control; *Po0.05 of (LPS+DF)-treated cells vs LPS alone.
Figure 4
Effect of defibrotide on fibrinolytic protein expression by unstimulated HMEC-1 (a-c panels) and HUVEC (d-f panels). ECs were incubated for 24 h (HMEC-1) or 48 h (HUVEC) with 800 mg/ml DF. After incubation, CM were collected and analyzed for the different parameters. DF did not affect PAI-1 antigen levels nor in HMEC-1 or HUVEC, while it significantly increased t-PA expression (both as antigen and activity) in both EC. *Po0.05 of DF-treated cells vs untreated control cells.
Defibrotide and endothelium A Falanga et al incubation times were required to obtain measurable amounts of these proteins in the two different EC systems. It is worth noticing that at all time points HMEC-1 expressed about 10 times more t-PA antigen and t-PA activity than HUVEC. In HMEC-1, in this condition, DF did not significantly affect PAI-1 antigen release compared to control cells, at any incubation time, including 24 h (Figure 4a ), whereas it significantly incremented t-PA antigen levels (control vs 200 mg/ml DF: 6.171.7 vs 14.271.8 ng/10 5 cells; Po0.05; Figure 2b ), in a dose-dependent manner (not shown). Finally, DF treatment significantly increased (Po0.05) t-PA activity in HMEC-1 (Figure 4c ): this effect was dose-and time-dependent (not shown).
Similar results were obtained with HUVEC. As observed for HMEC-1, DF did not affect the PAI-1 antigen levels of HUVEC at any incubation time, including 48 h (Figure 4d ). However, it significantly increased t-PA antigen expression (control vs 200 mg/ml DF: 0.5670.08 vs 0.8170.05 ng/10 5 cells; Po0.05) (Figure 4e ). The increment of t-PA antigen became evident after 48-h incubation with DF and was dose-dependent. The study of t-PA activity demonstrated that the observed increment in t-PA antigen actually translated into a significant increase in t-PA chromogenic activity (Figure 4f ).
Discussion
Recent clinical studies 7, 24, 25 have shown that DF is effective in resolving (in about 30% of cases) severe VOD, a life-threatening regimen-related complication of hematopoietic stem cell transplantation. 6 Severe hepatic VOD is associated with multiorgan failure and has a mortality rate approaching 100%. Although the pathogenesis of VOD remains to be completely clarified, clinical and pathologic data support the concept that damage to sinusoidal endothelium may play a major role in its development. EC activation is a common pathogenetic mechanism in vascular occlusions, and can be induced by a wide range of agents such as bacterial products, cytokines, oxidative products, lipoproteins and chemotherapeutic drugs. Changes in activated ECs include: loss of vascular integrity, expression of adhesion molecules, cytokine production, and changes in phenotype from antithrombotic to prothrombotic (ie loss of the surface anticoagulant molecules thrombomodulin and heparan sulphate, exposure of TF, reduced fibrinolytic potential due to enhanced PAI-1 and reduced t-PA release, loss of prostacyclinmediated antiaggregating effects). Elevated circulating PAI-1 levels in VOD add further evidence to an ongoing endothelium damage/perturbation in this syndrome. 9 DF shows antithrombotic properties in human vascular disorders 26 without significant systemic anticoagulant effects. A number of in vivo studies suggest that the endothelium may be a major target for DF activity. Indeed, studies in humans and in animal models show that DF administration affects the plasma levels of a number of proteins with antithrombotic activities, including t-PA and PAI-1, 27-30 TFPI, 30, 31 prostacyclin, 29, 32 thrombomodulin and P-selectin (Fareed J et al, Fibrinol Proteol 1998; 12(suppl 1): 59; abstract), and reduces platelet 33 and neutrophil 29 functions. However, no in vitro studies are available so far on the effects of DF on the expression of TF by macrovascular or microvascular ECs. Equally, no characterization of fibrinolytic proteins expressed by the two types of ECs upon direct exposure to DF has been conducted. Only one study has shown an increase of fibrinolytic activity by HUVEC alone, as measured by the shortening of the euglobulin lysis time, a test measuring the overall fibrinolytic activity. 18 Other in vitro studies have focused on DF effects on platelet and leukocyte hemostatic properties, [34] [35] [36] [37] or on thrombomodulin expression by HUVEC. 19 This is the first report on the impact of DF in vitro on endothelial procoagulant (TF) and fibrinolytic proteins (PAI-1 and t-PA). The observation is extended to two different types of EC, that is, from the micro-and macrovascular beds, which is important because ECs from the macrovasculature possess important physiological differences from those obtained from small vessels. The study was carried out on ECs activated by LPS, a known activator of endothelial procoagulant and fibrinolytic responses. Furthermore, LPS may be implicated in the onset of VOD, as it worsens in vivo the endothelial dysfunction associated to pretransplant conditioning regimens. 38 The results of our study demonstrate that DF significantly interferes with LPS-induced TF expression at the microvascular site, and is able to reduce the antifibrinolytic action of LPS on both micro-and macrovascular ECs. In our experiments, a high LPS dose was used according to a standard procedure utilized in our laboratory and established on the basis of published studies. [39] [40] [41] However, lower LPS doses (1.0 and 0.1 mg/ml) fully activated both EC types, and DF was equally active in counteracting the procoagulant and antifibrinolytic actions induced by all of these LPS doses (data not shown). TF is the major activator of blood coagulation. The reduction of TF expression on microvascular ECs may be important because fibrin deposition in the microvascular environment is involved in the mechanism of organ dysfunction and thrombotic microangiopathies.
The results of fibrinolytic assays show that DF is able to increase the fibrinolytic capacity of both HMEC-1 and HUVEC in the presence and also in the absence of LPS. The fibrinolytic activity reflects the balance between fibrinolysis activator and inhibitor. Indeed, treatment of both EC types with LPS alone induced the expression of t-PA antigen, but very importantly it upregulated its inhibitor PAI-1, which resulted in an overall reduction of EC fibrinolytic capacity. Differently, treatment of ECs with DF alone increased t-PA antigen, but did not affect PAI-1 levels, which translated in a net increase of EC fibrinolytic capacity, as measured by the t-PA activity assay. Consistent with that, we observed that DF not only further increased the LPSinduced t-PA expression, but also prevented the LPS-induced increase in PAI-1, which again resulted in a dose-dependent increase in the fibrinolytic activity. In conclusion, our data show that the increment of EC fibrinolytic potential by DF relies on its capacity to increase t-PA, but most importantly also on its capacity to inhibit PAI-1 increase. Previous data by Hizal et al. 18 have shown that CM from HUVEC incubated with DF have increased capacity to shorten the euglobulin lysis time, as a parameter of global fibrinolytic activity. We have analyzed the modulation by DF of the levels of profibrinolytic (ie t-PA) and antifibrinolytic (ie PAI-1) proteins and have measured the fibrinolytic activity by a specific t-PA chromogenic assay. Specificity of this assay was warranted by 98% inhibition of proteolysis of the chromogenic substrate by an anti-t-PA specific antibody. In our conditions an increase of fibrinolytic activity of two types of ECs, that is, HUVEC and HMEC-1, was detectable after treatment with DF.
These effects are consistent with and offer an explanation for in vivo observations showing an increase in plasma fibrinolytic activity and a decrease in PAI-1 in human subjects with vascular diseases and normal volunteers receiving DF. [26] [27] [28] [29] Our data show that DF utilized at any dose does not influence the levels of PAI-1; however, it prevents the upregulation of PAI-1 induced by LPS. We hypothesize that DF interferes with the mechanisms by which the proinflammatory stimulus LPS induces PAI-1 synthesis. Several in vitro studies demonstrate that various inflammatory cytokines and bacterial LPS induce the synthesis and release of PAI-1 from endothelium. In addition, clinical conditions of inflammation and septicemia, characterized by vascular stress due to high levels of circulating cytokines and/or bacterial products, show a rise in plasma PAI-1 levels, suggesting that elevated circulating levels of this molecule are to be considered among markers of ongoing endothelium perturbation in vivo. 42 An extensive damage of endothelium is involved in the pathogenesis of VOD. In this context, an important role has been attributed to the elevation of PAI-1, as it appears an independent diagnostic marker as well as a severity predictor of this transplant-related complication. 43, 44 In addition, there is also evidence that the resolution of VOD in patients receiving DF is associated with the reduction of plasma PAI-1 levels. 9 DF might act as a modulator of sinusoidal EC injury due to inflammatory mediators in this condition and might interrupt the endothelial-based processes that contribute to the progression of the syndrome.
Our data further support an association between the endothelium damage and the mechanism of VOD and suggest a role for DF in interfering with this process.
The induction of profibrinolytic and anticoagulant activities on EC by DF in our study occurred without causing apoptotic phenomena (data not shown). This confirms evidence recently shown by other authors on the lack of a proapoptotic activity of DF on HMEC-1 45 and shows for the first time the same effect on HUVEC as well. Eissner et al 45 have demonstrated that DF protects the endothelium from the proapoptotic effect of chemotherapy. Our study shows another protective mechanism of DF against the prothrombotic stimulus exerted by exogenous endotoxin. The anti-inflammatory action of DF may contribute to explaining the beneficial effects observed with this drug in pathological conditions of high endothelium toxicity, such as VOD.
